Navigation Links
Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug

WALTHAM, Mass., Aug. 18 /PRNewswire/ -- Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced today the successful completion of its Phase 1b randomized controlled multi-dose safety and pharmacokinetics study of LT-NS001, the Company's proprietary naproxen prodrug. The study, which was conducted from December, 2007 through July, 2008 in normal adult volunteers, showed that LT-NS001 was well-tolerated by the recipients. Moreover, when the subjects in the study were dosed twice daily with LT-NS001 for seven days, plasma concentrations of naproxen were within the therapeutic range.

LT-NS001 is a prodrug, which is converted in the bloodstream into naproxen, a non-steroidal anti-inflammatory drug (NSAID). Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class. In pre-clinical studies in rats and dogs, LT-NS001 was shown to cause significantly less damage to the gastrointestinal tract than equivalent doses of naproxen. LT-NS001 has completed pre-clinical toxicology testing and was previously evaluated in a Phase 1a randomized controlled single-dose and multiple-dose study and shown to be well tolerated.

"The robust pre-clinical data package for LT-NS001 suggests that this novel compound will provide patients with a drug that combines the efficacy and cardiovascular safety of naproxen while substantially decreasing the risk for gastrointestinal ulceration," said Dr. Mitchell Fink, the President and CEO of Logical Therapeutics, Inc. "The results from our recently completed P1b study of LT-NS001 are very encouraging, because they show that administration of the pro-drug leads to clinically useful circulating levels of naproxen."

Physicians and patients have accumulated more than 30 years of experience with naproxen, which is widely prescribed to treat pain and other signs and symptoms of inflammation caused by chronic conditions, such as osteoarthritis and rheumatoid arthritis. Despite its considerable efficacy and its good cardiovascular safety profile, naproxen, like most NSAIDs, can cause serious, even life-threatening, gastrointestinal complications. A safer alternative would fulfill a significant unmet medical need.

The company expects to begin enrolling subjects in its next clinical study of LT-NS001 later this year.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company based in Waltham, Massachusetts. Logical Therapeutics is developing drugs to treat a variety of medical conditions that are associated with excessive inflammation, including osteoarthritis and rheumatoid arthritis. For more information on Logical Therapeutics, visit the company's website at or send an email to

SOURCE Logical Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
6. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
7. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
8. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
9. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
10. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
11. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
Post Your Comments:
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... LEXINGTON, Massachusetts , November 24, 2015 ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ... Poulton , Chief Financial Officer, will participate in the Piper Jaffray ... City , NY on Tuesday, December 1, 2015, at 8:30 ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
(Date:11/24/2015)... , ... November 24, 2015 , ... InSphero AG, the ... cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... served on the management team and was promoted to Head of InSphero ...
Breaking Biology Technology:
(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/18/2015)... 2015  As new scientific discoveries deepen our understanding ... healthcare providers face challenges in better using that knowledge ... addition, as more children continue to survive pediatric cancer, ... old age. John M. Maris, M.D ., ... Philadelphia (CHOP) . --> John M. ...
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
Breaking Biology News(10 mins):